Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

10/19/2020 | 05:01pm EST

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to announce third quarter 2020 financial results and discuss recent business updates.

The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.


© Business Wire 2020
All news about SAGE THERAPEUTICS, INC.
08:07aSAGE THERAPEUTICS : Swings to Profit, Posts Higher Revenue in Q4
MT
07:19aSAGE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
06:48aSAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
06:31aSAGE THERAPEUTICS : Announces Fourth Quarter and Full Year 2020 Financial Result..
BU
06:31aSAGE THERAPEUTICS : Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q4 Revenue $..
MT
02/11SAGE THERAPEUTICS : to Present at Upcoming Investor Conferences
BU
02/10SAGE THERAPEUTICS : to Report Fourth Quarter and Full Year 2020 Financial Result..
BU
02/02SAGE THERAPEUTICS : Raymond James Reinstates Sage Therapeutics at Market Perform
MT
01/22SAGE THERAPEUTICS : BMO Capital Downgrades Sage Therapeutics to Market Perform F..
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
More news
Financials (USD)
Sales 2020 7,04 M - -
Net income 2020 -473 M - -
Net cash 2020 1 245 M - -
P/E ratio 2020 -9,38x
Yield 2020 -
Capitalization 4 957 M 4 957 M -
EV / Sales 2020 527x
EV / Sales 2021 231x
Nbr of Employees 675
Free-Float 87,7%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,85 $
Last Close Price 85,04 $
Spread / Highest target 120%
Spread / Average Target 17,4%
Spread / Lowest Target -17,7%
EPS Revisions
Managers and Directors
NameTitle
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.-1.70%4 677
MODERNA, INC.52.55%59 424
LONZA GROUP AG2.88%48 232
IQVIA HOLDINGS INC.6.63%36 544
CELLTRION, INC.-21.45%36 331
SEAGEN INC.-10.03%28 448